Two clinical studies have shown it may improve glycemic control and decrease insulin resistance in people with poorly controlled type 2 diabetes; However Servier is suspected of having marketed Mediator (benfluorex) at odds with the drug's medical properties.
Two clinical studies have shown. It may improve glycemic control. It may decrease insulin resistance in people with poorly controlled type 2 diabetes. However Servier is suspected of having marketed Mediator (benfluorex) at odds with the drug's medical properties.